Clinical Trials Logo

Clinical Trial Summary

This study is being done to find out if a drug called Rituxan (Rituximab) is safe and effective in treating people with chronic urticaria (hives) with persistent symptoms in spite of taking antihistamines.


Clinical Trial Description

Rituximab (Rituxan®) is a recombinant chimeric monoclonal antibody that binds to a molecule (CD20) that is present on the surface of B lymphocytes. The product is approved for the treatment of non-Hodgkin's lymphoma and has been investigated for the treatment of a number of autoimmune diseases including rheumatoid arthritis (Edwards 2004) and lupus (Looney 2004, Leandro 2002). As in most rheumatoid arthritis studies, the medication will be administered in this study as a series of two intravenous infusions given 2 weeks apart.

Many cases of chronic urticaria (hives) are though to be driven by an autoimmune mechanism (Kaplan 2002, Grattan 2002). It is our hypothesis that by interfering with the autoimmune process, potentially by decreasing the levels of autoantibodies or by interfering with other mechanisms that cause basophil and mast cell activation, improvments in signs and symptoms will be seen.

Given the effectiveness demonstrated for Rituximab in other autoimmune conditions, we will conduct a pilot open label investigation of 15 patients with chronic urticaria to determine the safety and effectiveness of Rituximab in this disease. All patients will receive the medication; there will be no placebo group in this study. Rituximab is not currently indicated for the treatment of this condition however.

We will evaluate the safety of the Rituximab in 15 patients with urticaria as well as studies of antibody levels and cellular function. We will also evaluate clinical outcomes such as itch score, sleep disturbance, and quality of life. After receivng the Rituximab treatment, we will begin to taper antihistamines and other medications used to control urticaria symptoms. ;


Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00216762
Study type Interventional
Source Johns Hopkins University
Contact
Status Terminated
Phase Phase 1/Phase 2
Start date January 2006
Completion date May 2007

See also
  Status Clinical Trial Phase
Terminated NCT03693625 - A Study to Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participants Previously Enrolled in a Fenebrutinib Chronic Spontaneous Urticaria (CSU) Study Phase 2
Recruiting NCT03545464 - COrticosteroids in acUte uRticAria in emerGency dEpartment Phase 3
Completed NCT00541255 - A Long-Term Examination of Asthma From Childhood Through Adolescence
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Terminated NCT00069329 - Anakinra to Treat Patients With Neonatal Onset Multisystem Inflammatory Disease N/A
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Terminated NCT00199238 - Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria Phase 2
Completed NCT02576041 - Effects of Bilastine on F1 Simulator Driving Performance in Patients Affected by Allergic Rhinitis and/or Urticaria Phase 4
Completed NCT02238249 - Study to Investigate the Safety and Efficacy of Alesion® in Japanese Paediatric Patients With Urticaria N/A
Completed NCT00724698 - Evaluation of Desloratadine When Used in Patients With Either Allergic Rhinitis or Chronic Idiopathic Urticaria
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT03296358 - Adding a Short Burst of Corticosteroid to the Conventional Treatment of H1 Antihistamines in Emergency Department. N/A
Completed NCT00130234 - Effect of Anti-IgE in Chronic Urticaria Phase 2
Completed NCT00795158 - How Desloratadine (Clarinex, Aerius) Affects Quality of Life in Patients With Chronic Idiopathic Urticaria (Have Had Hives for 6 Weeks or Longer)(Study P02988) Phase 3
Completed NCT00368823 - A Trial of Point of Care Information in Ambulatory Pediatrics Phase 3
Completed NCT02424799 - Study to Investigate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of GSK2646264 Phase 1
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT00751218 - A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735) Phase 4
Completed NCT03137069 - A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU). Phase 2
Recruiting NCT05115136 - Using Doxepin for Urticaria Phase 3